Nurix Therapeutics Inc’s filing revealed that its Chief Financial Officer van Houte Hans unloaded Company’s shares for reported $70243.0 on May 02 ’25. In the deal valued at $11.33 per share,6,198 shares were sold. As a result of this transaction, van Houte Hans now holds 33,724 shares worth roughly $0.4 million.
Then, JOHANNES VAN HOUTE bought 6,198 shares, generating $69,170 in total proceeds.
Before that, Hansen Gwenn sold 3,377 shares. Nurix Therapeutics Inc shares valued at $38,841 were divested by the Chief Scientific Officer at a price of $11.50 per share. As a result of the transaction, Hansen Gwenn now holds 61,516 shares, worth roughly $0.73 million.
Leerink Partners initiated its Nurix Therapeutics Inc [NRIX] rating to a Market perform in a research note published on March 17, 2025; the price target was $16. A number of analysts have revised their coverage, including BTIG Research’s analysts, who began to cover the stock in early December with a ‘”a Buy”‘ rating. BMO Capital Markets began covering NRIX with “an Outperform” recommendation on December 06, 2024. UBS started covering the stock on October 24, 2024. It rated NRIX as “a Buy”.
Price Performance Review of NRIX
On Monday, Nurix Therapeutics Inc [NASDAQ:NRIX] saw its stock fall -0.17% to $11.91. Over the last five days, the stock has lost -5.02%. Nurix Therapeutics Inc shares have fallen nearly -36.78% since the year began. Nevertheless, the stocks have fallen -27.82% over the past one year. While a 52-week high of $29.56 was reached on 01/27/25, a 52-week low of $8.18 was recorded on 04/10/25.
Levels Of Support And Resistance For NRIX Stock
The 24-hour chart illustrates a support level at 11.59, which if violated will result in even more drops to 11.27. On the upside, there is a resistance level at 12.10. A further resistance level may holdings at 12.29.
The most recent change occurred on October 11, 2024 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $41 price target.
